CompletedPhase 2NCT02260934
Rituximab and Belimumab for Lupus Nephritis
Studying Systemic lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Betty Diamond, M.D.Feinstein Institute for Medical Research
- Intervention
- Rituximab(biological)
- Enrollment
- 43 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2019
Study locations (15)
- University of Alabama, Birmingham, Birmingham, Alabama, United States
- UCLA Medical Center: Division of Rheumatology, Los Angeles, California, United States
- University of California, San Francisco, San Francisco, California, United States
- University of Colorado Denver: School of Medicine: Division of Rheumatology, Aurora, Colorado, United States
- Colorado Kidney Care, Denver, Colorado, United States
- Emory University School of Medicine, Atlanta, Georgia, United States
- Washington University in St. Louis, St Louis, Missouri, United States
- Feinstein Institute, North Shore Hospital, Manhasset, New York, United States
- New York University, Langone Medical Center, New York, New York, United States
- Weill Cornell Medical College: Hospital for Special Surgery -, New York, New York, United States
- Columbia University Medical Center, New York, New York, United States
- University of North Carolina School of Medicine:, Chapel Hill, North Carolina, United States
- Ohio State University Wexner Medical Center:, Columbus, Ohio, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- University of Texas Southwestern, Dallas, Texas, United States
Collaborators
Immune Tolerance Network (ITN)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02260934 on ClinicalTrials.govOther trials for Systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07107659Safety and Efficacy of ONT01 in LupusHospital for Special Surgery, New York
- RECRUITINGNANCT07558850Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune DiseasesThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGNCT06948110Deciphering the Genetic Architecture of Autoimmune DiseasesNational Human Genome Research Institute (NHGRI)
- RECRUITINGPHASE2NCT07409181A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)Boehringer Ingelheim
- RECRUITINGPHASE3NCT07332481A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseaseEMD Serono Research & Development Institute, Inc.
- RECRUITINGEARLY PHASE1NCT07526350MTS109 in Patients With Refractory Autoimmune DiseasesShanghai Changzheng Hospital
- RECRUITINGEARLY PHASE1NCT07490041Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic DiseasesThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGNANCT07470151Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology